Speratum
1 known investors
Speratum Biopharma develops RNA interference (RNAi) therapeutics for cancer and other hard-to-treat genetic diseases, using its proprietary NoPass RNAi design platform and Nano-In nanoparticle delivery system. Its lead candidate, NM-198, is based on the tumor-suppressor microRNA miR-198 and targets multiple oncogenic pathways in solid tumors.
Founders & leadership
CM
Christian Marín MüllerinFounder
Investors · 1
In the news
Frequently asked questions
- What does Speratum do?
- Speratum Biopharma develops RNA interference (RNAi) therapeutics for cancer and other hard-to-treat genetic diseases, using its proprietary NoPass RNAi design platform and Nano-In nanoparticle delivery system. Its lead candidate, NM-198, is based on the tumor-suppressor microRNA miR-198 and targets multiple oncogenic pathways in solid tumors.
- Who founded Speratum?
- Speratum was founded by Christian Marín Müller.
- Who are Speratum's investors?
- Speratum's investors include Carao Ventures.